Evidence map›Paper›PMID 34608451›Full record

ArticleiScience2021

A rapid test recognizing mucosal SARS-CoV-2-specific antibodies distinguishes prodromal from convalescent COVID-19.

Friederike Krempe, Lara Schöler, Benjamin Katschinski, Anke Herrmann, Olympia E Anastasiou, Carina Elsner, R Stefan Ross, Friedrich Scholz, Ulf Dittmer, Peter Miethe and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Friederike KrempeInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, North Rhine-Westphalia, Germany.
Lara SchölerInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, North Rhine-Westphalia, Germany.
Benjamin KatschinskiInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, North Rhine-Westphalia, Germany.
Anke HerrmannInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, North Rhine-Westphalia, Germany.
Olympia E AnastasiouInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, North Rhine-Westphalia, Germany.
Carina ElsnerInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, North Rhine-Westphalia, Germany.
R Stefan RossInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, North Rhine-Westphalia, Germany.
Friedrich ScholzSenova Gesellschaft für Biowissenschaft und Technik mbH, 99427 Weimar, Germany.
Ulf DittmerInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, North Rhine-Westphalia, Germany.
Peter Miethefzmb GmbH, Forschungszentrum für Medizintechnik und Biotechnologie, 99947 Bad Langensalza, Germany.
Vu Thuy Khanh Le-TrillingInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, North Rhine-Westphalia, Germany.
Mirko TrillingInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, North Rhine-Westphalia, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic poses enormous challenges to global healthcare sectors. To prevent the overburden of medical systems, it is crucial to distinguish individuals approaching the most infectious early phase from those in the declining non-infectious phase. However, a large fraction of transmission events occur during pre- or asymptomatic phases. Especially in the absence of symptoms, it is difficult to distinguish prodromal from late phases of infection just by RT-PCR since both phases are characterized by low viral loads and corresponding high Ct values (>30). We evaluated a new rapid test detecting IgG antibodies recognizing SARS-CoV-2 nucleocapsid protein using two commercial antibody assays and an in-house neutralization test before determining suitability for testing clinical swab material. Our analyses revealed the combination of the well-known RT-PCR and the new rapid antibody test using one single clinical nasopharyngeal swab specimen as a fast, cost-effective, and reliable way to discriminate prodromal from subsiding phases of COVID-19.

Indexed as

ImmunologyVirology

Identifiers

PMID34608451
PMCPMC8481626

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.